Introduction {#s1}
============

Acarbose is the prototype of alpha-glucosidase inhibitors and a widely used anti-diabetic drug. Acarbose is a pseudo-carbohydrate that competitively inhibits α-glucosidase, which is located in the brush border of the small intestine, leading to the delay of intestinal absorption of carbohydrates and therefore slows down the absorption of sugars ([@B8]), and reduced postprandial increases in blood glucose. Acarbose is primarily prescribed to patients with type 2 diabetes as monotherapy or as add-on to other antidiabetic drug treatment ([@B34]), especially in those with poorly controlled blood glucose by other antidiabetic drugs. Additional benefits have been noticed in diabetic patients treated with acarbose such as reduced risk for myocardial infarction and improved lipid profile and reduced levels of inflammatory cytokines in peripheral blood ([@B29]; [@B34]; [@B54]).

Recently, it has been observed that diabetic patients treated with acarbose have a decreased risk for developing rheumatoid arthritis (RA) ([@B14]) suggesting an anti-inflammatory effect by acarbose. The anti-inflammatory effect of acarbose has been experimentally proven in two mouse models of inflammation, namely collagen-induced arthritis (CIA) and a psoriasis model ([@B14]; [@B13]). In the two models of inflammatory diseases, daily administration of acarbose attenuated the diseases severity.

RA is a chronic autoimmune disease involving inflammation of the synovial joints that leads to cartilage degradation, bone erosion, and joint destruction. The cause of RA remains obscure, but interplay of genetic and environmental risk factors are thought to be responsible. Recently, dysbiosis of the gut microbiota has been considered as a contributor to RA etiopathogenesis ([@B47]; [@B43]; [@B44]). Interestingly, the microbiota dysbiosis in RA can be partially normalized by disease-modifying anti-rheumatic drugs (DMARDs) in those RA patients achieved remission of low disease activity ([@B62]) indicating that gut microflora biosis is associated with RA disease status. Patients with diabetes treated with acarbose have increased gut *Biffidobacterium longum* and *Enterococcus faecalis* ([@B54]). Moreover, mice fed with acarbose have increased lifespan ([@B31]; [@B30]). The enhanced longevity in acarbose treated mice is associated with changes in the gut microbiome ([@B53]). Given the linkage of decreased risk of developing RA in diabetic patients treated with acarbose, anti-inflammatory effect of acarbose in CIA, alteration of gut microbiome in mice treated with food supplement with acarbose, we hypothesized that acarbose exerts anti-inflammatory effects *via* alteration of the gut microbiota, and tested this idea in CIA by analyzing changes of bacterial composition before and after treatment with acarbose. Since CIA is known to be T helper 17 (Th17) cell dependent and displays T regulatory (Treg) cell functional defect ([@B16]; [@B41]), we focused on the immune changes of Th17 and Treg cells in the intestine and correlating them with changes of gut microbiota after acarbose treatment.

Materials and Methods {#s2}
=====================

Mice and Induction of CIA and Clinical Assessment of Arthritis {#s2_1}
--------------------------------------------------------------

Male DBA/1 mice (8--10 weeks old) were purchased from the Jackson Laboratory (Bar Harbor, ME). All mice were maintained in a specific, pathogen-free facility and housed in microisolator cages containing sterilized food, bedding and water. All animal experiments were performed under protocols approved by Institutional Animal Care and Use Committee of VA Portland Health Care System. Arthritis was induced by immunization with intradermal injection of 100 μg of chicken type II collagen (CII) (Chondrex, Inc., Seattle) emulsified 1:1 with complete Freund's adjuvant (CFA) and boosted on day 35 with an intraperitoneal injection of 25 μg of bacterial lipopolysaccharide (LPS). All mice were examined daily for the initial visual appearance of arthritis. Severity of arthritis was classified using a scoring system as described ([@B16]). Score 0: No evidence of erythema and swelling; Score 1: Erythema and mild swelling confined to the tarsals or ankle joint; Score 2: Erythema and mild swelling extending from the ankle to the tarsals; Score 3: Erythema and moderate swelling extending from the ankle to metatarsal joints; Score 4: Erythema and severe swelling encompassing the ankle, foot and digits, or ankylosis of the limb. The maximum score of each mouse is 16.

Treatment Protocols {#s2_2}
-------------------

To investigate whether acarbose prevents arthritis and suppresses joint destruction *in vivo*, we developed two experimental protocols based on published data ([@B14]; [@B13]). In the first protocol ([**Figure 1A**](#f1){ref-type="fig"}), mice were gavaged with 300 μl of acarbose 500 mg/kg, miglitol 500 mg/kg or drinking water daily starting at 7 days prior to induction of arthritis (before induction). In another protocol ([**Figure 1B**](#f1){ref-type="fig"}), mice were gavaged with 300 μl of acarbose 500 mg/kg, miglitol 500 mg/kg or drinking water every day starting on the day of arthritis induction (at induction). All mice were euthanized on day 55 after arthritis induction.

![Acarbose protected against collagen-induced arthritis. DBA/1 mice were treated with acarbose or miglitol or water either 7 days prior to **(A)**, Before Induction or at the time of arthritis induction (day 0) **(B)**, At Induction. Incidence and severity of arthritis were evaluated until day 55 post arthritis induction. **(C)** Joints of mice were harvested and stained with hematoxylin and eosin (H&E) and safranin-O. Representative photographs of histopathology showing synovitis, pannus formation, and marginal erosion of the joint and articular architectural changes in normal joint and mild, moderate and severe arthritis (pooled data of two experiments, n = 10--15 mice in each group). \*p \< 0.01; \*\*p \< 0.05.](fphar-10-01684-g001){#f1}

Cell Isolation and Purification of Spleen and Intestinal Lamina Propria T Cells {#s2_3}
-------------------------------------------------------------------------------

Spleen was removed and cells were isolated *via* single cell suspension by mechanical disruption through a 100 μm cell strainer. Lysis of erythrocytes was performed for spleens. To isolate cecum and colon intestinal lamina propria (LP), cecum and colons were removed, opened longitudinally, contents were flushed with ice-cold PBS containing 0.1% bovine serum albumin (BSA). Intestines were cut into 3 mm in length and incubated for 30 min at 37°C with RPMI 1640 containing 3% fetal bovine serum (FCS), 5 mM EDTA, 10 mM HEPES, 100 U/ml penicillin, and 100 μg/ml streptomycin (Gibco, USA) with and 1 mM dithiothreitol (DTT, Fisher Scientific, Pittsburgh) with gentle shaking at 37°C for 30 min to remove the epithelium and intraepithelial lymphocytes. Tissues were washed with PBS containing 0.1% BSA twice, then followed by incubation with 0.2 mg/ml collagenase II (Sigma) and 0.1 mg/ml DNase I (Roche) with stirring at 37°C for 45 min. Cells were then filtered through a 40 μm cell strainer and harvested at the interface of a 40%/70% Percoll (GE Healthcare) gradient, then washed in PBS containing 0.1% BSA for assays.

Flow Cytometry {#s2_4}
--------------

Intracellular staining was performed as follows. Cells were stimulated with phorbol myristate acetate (50 ng/ml, Calbiochem) plus ionomycin (500 ng/ml, Merck & Company) for 4 h, with Golgi Plug (BD Biosciences). After cell surface staining with antibodies to CD4, CD25 and CCR6 (BioLegend), cells were fixed and permeabilized Fix/Perm buffer (eBioscience) overnight at 4°C. Antibodies to Helios, IL-17A and Foxp3 (eBioscience) were added and incubated for 30 min at 4°C. Cells were acquired with a BD LSRII and data were analyzed using FlowJo (V10, USA) software.

Histopathology of Arthritis {#s2_5}
---------------------------

Mouse joint tissues were removed, fixed in 10% formalin, decalcified, embedded in paraffin and sectioned at 6 μm. Sections were stained with hematoxylin and eosin, Safranin-O and toluidine blue to detect synovitis, pannus formation, and marginal erosion of the joint and articular architectural changes.

### Anti-CII Antibody Quantification {#s2_5_1}

Mouse serum samples were collected at the end of the experiment. Antibodies of different isotypes to chicken and murine CII (Chondrex, Seattle, WA) were determined by enzyme linked immunosorbent assay (ELISA), as previously described ([@B15]). Microtitre plates were coated with 5 μg/well of native chicken or murine CII in potassium phosphate coating buffer (pH 7.4) overnight at 4°C, followed by blocking with an overnight incubation at 4°C with blocking buffer (2% BSA in PBS). Serum samples diluted at 1:4,000 in PBS containing 0.05% Tween 20 and 0.5% BSA were incubated 1 h at room temperature. Goat anti-mouse IgG, IgG1, IgG2a and IgG2b conjugated to alkaline phosphatase (Jackson ImmunoResearch Laboratorie) diluted at 1:5,000 were incubated for 30 min at room temperature to detect anti-CII or anti-mouse antibody isotypes and IgG subclasses. The optical density at 450 nm was read with a Molecular Devices plate reader (Molecular Devices, Menlo Park, CA). Antibody levels were expressed as arbitrary units with reference to a standard serum.

### Multiplex Cytokine Assay {#s2_5_2}

Serum levels of various cytokines (IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-13, IL-17A, IL-17F, IL-21, IL-22, IFN-γ, and tumor necrosis factor (TNF)-α) were determined using the LEGENDplex™ Mouse Th Cytokine Panel (13-plex) array (Biolegend) according to the manufacturer's protocol. The data were collected on a LSR II flow cytometer and analyzed using the LEGENDplex™ software version 7.0 (Biolegend).

### Fecal Pellet Collection {#s2_5_3}

Fecal pellets for microbial community analysis were collected before arthritis induction (day −7), at arthritis induction (day 0), onset of arthritis (day 37), and at the termination of the experiment (day 55). Fecal samples and cecal contents from mice housed under specific pathogen-free conditions were harvested under sterile conditions in a 1.5 ml Biopure tube (Eppendorf) and immediately snap frozen and stored at −80°C until processing for DNA isolation.

### 16S rRNA Gene Sequencing {#s2_5_4}

DNA was isolated from fecal pellets and cecal contents using PowerSoil DNA Isolation Kit (MoBio Laboratories Inc., Carlsbad, CA) according to the manufacturer's instructions. DNA concentration was confirmed by Nanodrop spectrophotometer prior to normalization to \~20 ng/µl. Quantitative real-time PCR (qRT-PCR) amplification was performed using a set of primers targeting the V4 hypervariable regions of the 16S rRNA gene using the 515F--806R primers and sequenced on the Illumina MiSeq platform ([@B12]). The primers used were as follows: FWD : GTGCCAGCMGCCGCGGTAA; REV : GGACTACHVGGGTWTCTAAT (original, rev-barcoded: 515F-806R). Each PCR amplification reaction contained 1 μl of DNA extract, 0.2 mM dNTPs, 0.2 mM forward primer, 1 μl reverse primers, 48 μl of master mix containing 1× colorless reaction buffer, 1.5 mM MgCl~2~ and 1.25 U of polymerase enzyme. The reaction volumes were placed in a thermocycler and run through the following conditions: 94°C for 3 min (initial denaturation), followed by 35 cycles of 94°C for 45 s (denaturation), 55°C for 40 s (annealing) and 72°C for 1.5 min (extension) and ending with a last step of 72°C for 10 min.

The final steps of library preparation were performed with the Illumina Miseq V2 kit. The DNA library was diluted to 4 nM and denatured with NaOH for 5 min. The library was then diluted to a final concentration of 6.6 pM in hybridization buffer HT1 (Illumina), spiked with 5% PhiX control heated to 96°C for 2 min prior to incubation for 5 min on ice and then loaded onto the MiSeq cartridge. A 500 cycle MiSeq Reagent Kit v2 was used and run on the Illumina Miseq instrument.

### 16S rRNA Gene Sequencing Analysis and Bioinformatics {#s2_5_5}

Primers and sequence adapters were removed with the Illumina MiSeq Reporter (version 2.5) and further processed using the Quantitative Insights Into Microbial Ecology (QIIME) pipeline version 1.9.0 ([@B11]), the Vegan package in R ([@B23]) and Linear discriminant analysis (LDA) effect size (LEfSe) ([@B50]). To adjust for multiple comparisons the Benjamini--Hochberg method was used ([@B7]). Taxonomy was assigned with the BLAST consensus method of QIIME, using the most recent version of the GreenGenes database (v.13.8) ([@B22]). Chimeric sequences were detected and removed using the blast_fragments approach implemented in identify_chimeric_seqs.py. Operational taxonomic units (OTU) were picked using UCLUST at 97% sequence identity. Rarefaction was performed to subsample each sample to 17,000 reads prior to comparing the abundance of OTU across samples. We assessed α-diversity with observed OTU count and the Chao1 Estimator for microbial richness. Between group β-diversity was evaluated with unweighted UniFrac distances and principal coordinate analysis in QIIME and statistically evaluated using PERMANOVA. LEfSe analysis was implemented in Galaxy (version1.0) and performed using standard parameters (p \< 0.05 and LDA score 2.0).

### Statistical Analysis {#s2_5_6}

Nonparametric data were compared using Mann--Whitney U test, and parametric data were compared using Student's t-test. All statistical analyses were calculated in Prism (GraphPad Prism 5). Differences were considered to be statistically significant when P \< 0.05.

Results {#s3}
=======

Acarbose Suppressed CIA {#s3_1}
-----------------------

Acarbose dissolved in drinking water was administered *via* gastric gavage at 500 mg/kg daily. This dose was chosen based on previously published protocol in which 500 mg/kg was effective while 100 mg/kg did not have effect on arthritis or psoriasis models ([@B14]; [@B13]). Miglitol was included as a control drug to acarbose. Miglitol is a second generation of α-glucosidase inhibitor ([@B51]). While greater than 98% of orally dosed acarbose is not absorbed ([@B20]), miglitol is completely absorbed by the small intestine ([@B51]; [@B20]) and therefore, an appropriate control for gut activity of acarbose. Oral administration of acarbose significantly suppressed CIA when given prior to or at the time of arthritis induction and reduced incidence of CIA when given prior to induction of arthritis ([**Figure 1**](#f1){ref-type="fig"}). The arthritis inhibition effect of acarbose, however, is less potent if given at the time of arthritis induction. The arthritis inhibition effect was demonstrated by histological analysis. In the group of animals treated by acarbose 7 days prior to arthritis induction, 37% of arthritic joints were identified as mild, whereas only 14% of arthritic joints were mild in the drinking water treated group ([**Table 1**](#T1){ref-type="table"}). In contrast, in the animals treated at induction, 52% of arthritic joints were identified as severe with joint structure destruction in drinking water treated animals, compared with only 16% of the joints belonged to the severe category in acarbose group ([**Figure 1**](#f1){ref-type="fig"} and [**Table 1**](#T1){ref-type="table"}). Miglitol also had arthritis inhibiting effects but much less potent than acarbose ([**Figure 1**](#f1){ref-type="fig"} and [**Table 1**](#T1){ref-type="table"}).

###### 

Histopathological severity of arthritis^1^.

  Treatment   Number of joints assessed   Severity (%)                
  ----------- --------------------------- --------------- ----------- ------------
  Water       35                          5 (14)          12 (34)     18 (52)
  Miglitol    36                          11 (31)\#       16 (44)\#   9 (25)\*\*
  Acarbose    38                          14 (37)\*\*\*   18 (47)\#   6 (16)\*

\*P = 0.001 (Acarbose vs control).

\*\*p = 0.02 (Miglitol vs control).

\*\*\*p = 0.03 (Acarbose vs control).

\#Not statistically significant.

^1^The severity of arthritis in each joint was classified as mild, moderate or severe based on the following criteria: mild, minimal synovitis, cartilage loss and bone erosions limited to discrete foci; moderate, synovitis and erosions present but normal joint architecture intact; severe, synovitis, extensive erosions, and joint architecture disrupted (as shown in [**Figure 1C**](#f1){ref-type="fig"}, ([@B59]; [@B15]).

Modulation of Immune Response by Acarbose {#s3_2}
-----------------------------------------

We next sought to identify if α-glucosidase inhibitors modulates the antigen-specific systemic immune response, thereby resulting in protection against CIA. Immunized DBA/1 mice are known to cause elevation of anti-CII antibodies and these antibodies are pathogenic. We measured CII-specific anti-chicken CII and murine CII autoantibody production in serum. Mice treated with acarbose started before arthritis induction showed a significant reduction in levels of anti-chicken CII total IgG, IgG1 and IgG2b antibodies compared to control mice ([**Figure 2**](#f2){ref-type="fig"}). No significant changes were observed in the group of mice treated starting at arthritis induction ([**Figure 2**](#f2){ref-type="fig"}). We did not find any difference between groups in CII type II anti-murine autoantibodies. We measured levels of pro- and anti-inflammatory cytokines. Mice treated with acarbose significantly reduced IL-9 (*P \<* 0.05) and IL-6 (*P \<* 0.001) while miglitol reduced IL-9 (*P \<* 0.05) compared with mice gavaged with water alone in the protocol of treatment starting before arthritis induction. Mice treated with acarbose also showed a significantly decreased level of IL-6 in mice treated at arthritis induction (*P \<*0.05). None of the α-glucosidase inhibitors treated mice in both protocols showed any significant changes in cytokines levels of IL-10 and interferon (IFN)-γ compared with water-treated controls ([**Figure 2**](#f2){ref-type="fig"}). For the remaining analyzed serum factors related to T-cell activation status (IL-4, IL-5,IL-13, IL-17A, IL-17F, IL-21, IL-22, IL-23 and TNF), no obvious differences were detected or a comparative analysis was not feasible because of serum levels being predominantly or completely below the detection limit of the applied assays in either mouse group (data not shown).

![Anti-collagen type II autoantibody and cytokine production. Mice were treated with acarbose, miglitol or water as in [**Figure 1**](#f1){ref-type="fig"} (Before Induction or At Induction). Serum levels of IgG, IgG1, IgG2a and IgG2b anti-collagen type II were determined by specific enzyme-linked immunosorbent assay **(A)** and concentrations of cytokines were determined by the LEGENDplex mouse Th cytokine panel (13-plex) array **(B)**. Data were expressed as mean ± SEM. These results consist of the average of two independent experiments, five mice per group. \*p \< 0.05, \*\*\*p \< 0.01, vs control group.](fphar-10-01684-g002){#f2}

Modulation of α-Glucosidase Inhibitor Treatment in Th17 and T Regulatory (Treg) Cells {#s3_3}
-------------------------------------------------------------------------------------

To confirm that the treatment with α-glucosidase inhibitors modulate innate and intestinal immune system, we compared spleen and large intestine LP lymphocytes by flow cytometry. We focused on Th17 and Treg cells since Th17 and Treg imbalance is involved in the pathogenesis of CD4^+^ T cells in DBA/1 mice during CIA ([@B16]; [@B41]). There was no difference of Th17 cells was detected in the spleen in either treatment protocols, or in gut LP in mice treated at arthritis induction groups. On the other hand, the frequency of Th17 cells was significantly decreased in the intestinal sites in both acarbose and miglitol when treatment started prior to arthritis induction ([**Figure 3**](#f3){ref-type="fig"}). To examine the anti-inflammatory response in the mice, we chose two well-characterized markers, Helios^+^ and CCR6^+^ of Treg cells which have been previously demonstrated to provide robust results and reproducible result in Treg cells. Mice treated with acarbose prior to arthritis induction had significantly increased CD4^+^CD25^+^Foxp3^+^ Treg cells as well as elevation of Helios and CCR6 as demonstrated in both percentage and absolute Treg cell numbers ([**Figure 3**](#f3){ref-type="fig"} and [**Table 2**](#T2){ref-type="table"}). Treatment with miglitol also observed increased percentage of CD4^+^CD25^+^Foxp3^+^ Tregs (*P \<*0.01) and CCR6^+^ (*P \<* 0.05) in the mucosal sites ([**Figure 3**](#f3){ref-type="fig"}), but the increased absolute number of Treg cells did not reach statistical significance ([**Table 2**](#T2){ref-type="table"}). Whereas, neither CD4^+^CD25^+^Foxp3^+^Helios^+^ nor CCR6^+^ response to α-glucosidase inhibitors was observed in the groups when treatment started at arthritis induction ([**Figures 3C, D**](#f3){ref-type="fig"}). This confirmed α-glucosidase inhibitors have a prophylactic effect on lymphocytes resided in the gut lamina propria. α-glucosidase inhibitors suppressed induction of Th17 cells and with a trend towards an increase of Treg cells. As αglucosidase inhibitors modulated Th17/Treg subsets, we addressed the question of whether α-glucosidase inhibitors could affect the gut microbiota at the site which may further adjust the differentiation of Th cells.

![α-glucosidase inhibitor treatment on the mouse spleen and intestinal immune systems. Mice were treated with acarbose, miglitol or water as in [**Figure 1**](#f1){ref-type="fig"} (Befosre Induction or At Induction). The number of Th17 and Treg cells in mouse spleen and gut lamina propria was analyzed using flow cytometry. **(A)** Th17 cells: Lymphocytes were stimulated and stained with CD4 and IL-17A antibodies. Each dot plot shows data from one representative mouse of each group. The number in the right upper quadrant indicates the percentage of CD4+IL-17+ lymphocytes. Bar graphs represent the data expressed as mean ± SEM. **(B**--**E)** Treg cells: Percentage of Treg cells (CD4^+^CD25^+^Foxp3^+^) **(B)**, Helio^+^ Treg cells (CD4^+^CD25^+^Foxp3^+^Helios^+^) **(C)** and CCR6^+^ Treg cells (CD4^+^CD25^+^Foxp3^+^CCR6^+^) **(D)** was quantified by flow cytometry. Each dot plot shows data from one representative mouse of each group. **(E)** Bar graphs represent the data of total Treg, Helio^+^ Treg and CCR6^+^ Treg cells expressed as mean ± SEM. These results were average of two independent experiments, 7-10 mice per group. \*p \< 0.05, \*\*p \< 0.01, vs control group.](fphar-10-01684-g003){#f3}

###### 

Acarbose induced increase of Treg cells in lamina propria^1^.

                         Spleen     Lamina Propria                                                                                               
  ---------------------- ---------- ---------------- ----------- ------ ----------- ------ ------------- ------- ----------- ------- ----------- -------
  **Before Induction**                                                                                                                           
  Water                  514 ± 64                    171 ± 91           355 ± 111          647 ± 182             519 ± 117           360 ± 97    
  Miglitol               525 ± 51   0.67             138 ± 22    0.31   385 ± 30    0.44   883 ± 331     0.08    697 ± 281   0.10    430 ± 135   0.23
  Acarbose               498 ± 71   0.62             171 ± 107   1.00   349 ± 77    0.20   1,086 ± 274   0.001   908 ± 236   0.000   570 ± 129   0.001
  **At Induction**                                                                                                                               
  Water                  496 ± 94                    168 ± 91           387 ± 84           550 ± 123             348 ± 74            400 ± 132   
  Miglitol               502 ± 59   0.88             163 ± 54    0.87   396 ± 72    0.81   627 ± 239     0.40    483 ± 207   0.08    483 ± 197   0.33
  Acarbose               457 ± 76   0.35             159 ± 70    0.81   355 ± 70    0.42   566 ± 209     0.85    348 ± 133   1.00    423 ± 159   0.76

^1^Absolute Treg cell numbers were derived from % of Foxp3^+^ or Foxp3^+^/CCR6^+^ or Foxp3^+^/Helios^+^ CD4^+^/CD25^+^ T cells out of a total of 50,000 cells acquired on flow cytometry. Pooled data of two experiments with n = 7--10 mice in each group. The values are mean ± SD.

\*p values are comparison of miglitol or acarbose treated group with water treated.

Alteration in Microbial Community and Function by α-Glucosidase Inhibitors {#s3_4}
--------------------------------------------------------------------------

Fecal pellets were collected for analysis by V4 rRNA sequencing before treatment (on day −7 or 0), during onset of arthritis (on day 37) and the end of treatment (on day 55). Cecal contents were collected at the end of the experiments (on day 55). Reads were clustered into 1,010  ± 228 OTUs at 97% identity. We then examined whether fecal microbiota richness and diversity, as estimated by the number of observed OTUs and Chao1 estimators, were changed by α-glucosidase inhibitors treatment in different treatment arms ([**Figure 4A**](#f4){ref-type="fig"}). Rarefaction curves plateaued after 15,000 reads per sample, approximating a saturation phase. The variability of OTUs estimated in controls was lower compared to the acarbose groups in animals treated before or at the time of arthritis induction. As shown by the Chao1 estimator, bacterial diversity and richness in CIA control mice with arthritis was significantly lower than in acarbose treatment groups (P \< 0.05). All measures indicate a much higher biodiversity within the acarbose treatment than in water control samples ([**Figure 4A**](#f4){ref-type="fig"}).

![Alteration in microbial community by α-glucosidase inhibitors. Mice were treated with acarbose, miglitol or water as in [**Figure 1**](#f1){ref-type="fig"} (Before Induction or At Induction). **(A)** Alpha diversity of intestinal microbiota as represented by number of observed OTUs and Chao1 estimator. **(B)** Principal coordinate analysis (PCoA) plots displaying Beta diversity of microbiota by treatment group using unweighted UniFrac distances. **(C)** The composition of gut microbiota in colon at the phylum (left) and genus (right) levels. Each phylum/genus is represented by different color and its proportion of relative abundance per sample. Genera were filtered for those with ≥0.1% of total abundance. If full identification was not possible, f\_ or g\_ alone was used for family or genus, respectively. **(D)** Cladogram representing the most differentially abundant taxa enriched in microbiota from α-glucosidase inhibitors and control mice generated from LEfSe analysis. The central point represents the root of the tree (Bacteria), and each ring represents the next lower taxonomic level (phylum through genus). The diameter of each circle represents the relative abundance of the taxon. **(E)** Relative abundance of *Lactobacillus*, *Anaeroplasma*, *Adlercreutzia, RF39, Oscillospira, Ruminococcus* and *Desulfovibrio*; asterisks indicate level of significance by Mann--Whitney U test. These results consist of the average of two independent experiments, 7--10 mice per group. Mean values ± SEM are plotted; \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001.](fphar-10-01684-g004){#f4}

We next sought to evaluate overall differences in beta-diversity between the microbial communities. We applied the unweighted UniFrac metric ([@B39]) to calculate pairwise distances between samples, which takes into account phylogenetic distances among microbes and their presence or absence. As shown from principal coordinate analysis (PCoA) plot ([**Figure 4B**](#f4){ref-type="fig"}), at the end time point a clear separation between the acarbose and the control group was observed in both before and at arthritis induction treatment groups in the colon and cecum (P \<0.05, permutation test with pseudo F-ratio). Within the miglitol microbial community cluster, there appears to be clear difference in treatment groups (P \< 0.05), but not observed in groups treated before arthritis induction compared with control. Notably in the cecum, we also found significant differences between groups in both before and at arthritis induction treatment groups (P \<0.05) ([**Figure 4B**](#f4){ref-type="fig"}). This evidence suggested that the overall composition of the microbial community was significantly changed in the α-glucosidase inhibitor treatment groups.

We hypothesized that there would be compositional changes in the intestinal microbiota between treatment groups. At the phylum level, *Firmicutes* and *Bacteroidetes* were the two largest phyla represented in each group ([**Figure 4C**](#f4){ref-type="fig"}). In the prophylactic groups, *Firmicutes* and *Bacteroidetes* exhibited large shifts during treatment. *Firmicutes* were significantly reduced after arthritis onset and the ratio of *Firmicutes* increased in the α-glucosidase inhibitors treatment groups. In the group of acarbose treatment before arthritis induction, *Firmicutes* was higher before immunization (68.63%), lower at arthritis onset (38.97%) and restored after treatment (66.75%). The microbiota composition was similar in the miglitol treatment group. The proportional abundance of *Firmicutes* was higher before immunization (76.82%) and decreased with arthritis onset (32.48%) and increased after treatment (67.60%). In contrast, *Firmicutes* dropped after immunization but was unable to be restored (52.71%) in controls. This trend was also detected in the treatment groups, at the end of the study α-glucosidase inhibitors restored *Firmicutes* which was significant (P \<0.01).

To determine whether the intestinal microbiota contributes directly to arthritis progression, we generated a cladogram with LEfSe to detect bacterial taxa with significantly different abundances between groups ([@B50]). A comparison between the α-glucosidase inhibitor treatment and control groups showed that 42 OTUs were significantly different from acarbose group and 38 OTUs were in miglitol groups among samples of treatment arms at genus level ([**Figures 4C, D**](#f4){ref-type="fig"}). In addition, in the groups which treatment started prior to arthritis induction, LEfSe identified 19 discriminative features from acarbose groups but 8 OTUs were significantly higher in the miglitol group. As shown above, to identify the effect of α-glucosidase inhibitors on gut bacteria, we found that genus *Lactobacillus, Anaeroplasma, Adlercreutzia*, and *RF39* was significantly higher in control groups than the α-glucosidase inhibitors treated littermates, while *Oscillospira*, *Desulfovibrio* and *Ruminococcus* were enriched in the α-glucosidase inhibitors treated littermates compared with the control groups in the treatment arm ([**Figure 4E**](#f4){ref-type="fig"}). We did not notice any significant difference between acarbose when compared with miglitol. Thus, we identified microbes which were altered between α-glucosidase inhibitors groups and control in the development of arthritis, suggesting roles of α-glucosidase inhibitors in host metabolic development.

Discussion {#s4}
==========

In this study, we have shown that administration of α-glucosidase inhibitors, especially acarbose before arthritis induction has a potent modulatory effect upon reversing joint inflammation both clinically and histologically in CIA, but the effect was much less significant when treatment started at the time of arthritis induction. These results are consistent with those by Chen and colleagues ([@B14]) in which acarbose gained both clinical and histological improvement of CIA. The notable immunological feature in CIA mice is the excessive production of autoantibodies against CII which may initiate arthritis. Our data suggest that high titers of anti-chicken CII antibodies like IgG, IgG1 and IgG2b production in control mice may contribute to the more severe disease. Furthermore, acarbose treated mice produced significantly lower levels of these antibodies, which may prevent the development of arthritis. Another critical feature of CIA is the over expression of pro-inflammatory cytokines that could contribute to inflammation, articular destruction, and the comorbidities associated with arthritis. There is evidence suggesting that IL-9 production in Th17 cells has been related to autoimmune disease including type 1 diabetes ([@B42]), asthma ([@B35]), and experimental autoimmune encephalomyelitis ([@B38]). Since IL-9 is a Th17-associated cytokine, a few studies evaluated the function of IL-9 in the pathogenesis of RA ([@B19]). IL-9 has recently been found to be overexpressed in RA synovial tissues and correlated with the degree of histological organization of B and T cells in ectopic lymphoid structures ([@B17]). Also, IL-9 was related to the presence of RA-related autoantibodies ([@B32]). Our findings suggest that IL-9 is overexpressed in CIA control mice compared to that in mice prophylactic treatment with acarbose. In addition, mice treated with miglitol resulted in significant decreased expression of IL-9, indicating α-glucosidase inhibitors regulating IL-9 development of CIA. Numerous studies suggest that IL-6 contributes to the pathophysiology of RA. An IL-6 inhibitor is a desirable therapeutic option in the treatment of RA ([@B24]). Both acarbose and miglitol have been reported to suppress IL-6 levels in obese subjects ([@B2]; [@B21]). In our study, the concentration of IL-6 was significantly lower in acarbose treated animals, which is consistent with the previous report in CIA mice ([@B14]).

The imbalance between Th17 and Treg cells has been tightly related to the pathogenesis of RA ([@B40]) and CIA ([@B15]; [@B16]; [@B1]; [@B57]; [@B41]). In our study, we did not notice any differences of Th17/Treg cells in the spleen between groups regardless whether mice were treated before or at the time of arthritis induction. Notably, our data on α-glucosidase inhibitors suggest that most of its anti-inflammation effect is due to inhibition of intestinal mucosal immunity. α-glucosidase inhibitors suppressed Th17 responses associated with a relative induction of a Treg subset response. The proportion of Th17 cells in the gut LP was significantly lower in the mice treated with acarbose and migltiol before arthritis induction than those treated with drinking water. This suggests that the consumption α-glucosidase inhibitors are not simply immunosuppressive but immunoregulatory because it also favored the anti-inflammatory effect of Treg cells. Recently, it has been demonstrated that Helios-enriched Treg might exert increased suppressive effects ([@B61]; [@B6]). In addition, Helios expression in CD4^+^ T cells correlated inversely with the serum C-reactive protein level in RA patients ([@B55]). CCR6^+^Treg cells preferentially migrated to the colon during inflammation ([@B37]). Prophylactic administration of acarbose not only increased CD4^+^CD25^+^Foxp3^+^ T cells but also elevated Helios and CCR6 in the intestine. Prophylactic administration of miglitol also led to an increased number of CD4^+^CD25^+^Foxp3^+^ T cells and elevated expression of CCR6.

Host-commensal interactions have increasingly been related to the induction of numerous autoimmune inflammatory diseases both in experimental animals and in humans including inflammatory bowel disease ([@B60]), diabetes ([@B10]), multiple sclerosis ([@B33]) and RA ([@B47]). Previous work has emphasized the anti-inflammatory effect of short chain fatty acids (SCFA) in elevating chronic inflammatory disease, α-glucosidase inhibitors prevent the digestion of the carbohydrates and non-digestible carbohydrates generally provide the main sources of energy for the microbial organism that produce SCFA in the large intestine. Intake of acarbose and miglitol results in larger proportions of undigested carbohydrates reaching the ileum and colon ascendens where they are digested by bacteria to form SCFA ([@B29]). It has been shown by several studies that SCFA are potent inducer of Treg cells and modulate cytokine production ([@B3]; [@B26]; [@B31]; [@B36]). Considering acarbose is almost not absorbed from the gastrointestinal tract, whereas, miglitol is well absorbed with 100% systemic bioavailability, these two drugs may reestablish the Th17/Treg to a "normal" state in the gut *via* different mechanisms. Smith and colleagues observed that the commensal bacterial metabolites in the colon - SCFA, selectively expand the frequency and number of Treg cells in the large intestine mediated by the G-protein-coupled free fatty acid receptor 43 (GPR43) ([@B31]). SCFA, particularly butyrate has been recognized to regulate inflammation and immune responses which up regulated the production of anti-inflammatory cytokines and reduce IL-6 levels, resulting in the induction of CD4^+^CD25^+^ Treg cells ([@B5]). Scheppach and colleagues ([@B46]) reported an increase in both butyrate concentration and excretion with the treatment of acarbose. The non-absorbed acarbose reaches colon to provide extra carbohydrates for commensal bacteria to digest for more SCFA production. This may explain the more potent anti-inflammation effects of acarbose than miglitol.

We undertook studies to define the community structure of the fecal microbiome in CIA arthritic models using high-throughput 16S rRNA gene sequencing. We observed more richness within α-glucosidase inhibitors treated groups than the control littermates. At the phylum level, more specific alteration was observed, including decreases in the ratio of member of the *Firmicutes* to *Bacteroidetes* at arthritis onset which was restored after treatment while controls were unable to restore *Firmicutes.* Several intestinal species of *Firmicutes* produce SCFA butyrate, which is known to play a key role in providing major energy source for colonic intestinal epithelial cells maintaining integrity of the gut epithelium, inhibiting inflammatory response, helping regulating the production and development of Treg cells in the colon ([@B49]).

At genera level, five genera flourished after treatment with α-glucosidase inhibitor, including *Oscillospira*, *Ruminococcus* and *Desulfovibrio*, while the abundance of *Lactobacillus*, *Anaeroplasma*, *Adlercreutzia Ruminococcus* and *RF39* were increased in mice with arthritis. Several intestinal organisms identified in this study as being altered in animal models have been demonstrated to be associated with RA. *Lactobacillus* was over-represented in the fecal, dental, and salivary microbiota of patients with RA than the healthy controls, and its abundance was particularly pronounced in severe cases ([@B3]; [@B54]; [@B9]). Also, *Lactobacillus* was significantly more abundant in CIA-susceptible mice prior to arthritis onset than in CIA-resistant mice ([@B33]), although previous clinical study demonstrated enhanced abundance of *Lactobacillus* with acarbose treatment in prediabetic patients ([@B63]). On the other hand, we observed the relative abundance of *Oscillospira* to be greatly enriched following α-glucosidase inhibitors. *Oscillospira* is an enigmatic bacterial genus that has never been cultured, but is recently detected by 16S rRNA gene sequencing. Some *Oscillospira* species are likely to be able to utilize host glycans and can probably produce the SCFA, butyrate ([@B28]). *Oscillospira* has been reported to have negative association with inflammatory diseases and lower body mass index, and is positively associated with lean and healthy subjects ([@B56]; [@B25]; [@B27]). Notably, *Oscillospira* is significantly reduced in patients with Crohn's disease ([@B58]) and also reduced in pediatric nonalcoholic steatohepatitis, an inflammatory disease of the liver characterized by deposition of large amounts of fat in the liver ([@B28]). These studies imply that *Oscillospira* helps in reducing arthritis. In addition, *Ruminococcus* have been reported to be capable of fermenting glucose, xylose and indigestible diet fiber and produce acetate *via* acetyl-CoA from pyruvate and Wood--Ljungdahl pathway ([@B18]). *Ruminococcus bromii* is suggested as a keystone species for the degradation of resistant starch in the human colon which fermented by intestinal microbiota to secrete SCFA. Scher and colleagues ([@B48]) showed a significant lower level in members of the bacterial genus *Akkermansia, Ruminococcus*, and *Pseudobutyrivibrio* in fecal samples from patients with psoriatic arthritis. Also, we found the abundance of genus *Desulfovibrio*, a gram-negative, aerotolerant, non-spore former was at a higher level following α-glucosidase inhibitors than their counterparts. *Desulfovibrio* species work synergistically with *Prevotella* species to degrade mucin ([@B4]). In addition, *Desulfovibrio*, *Prevotella*, *and Oscillibacter* can utilize microbial exopolysaccharides synthesized by *Bifidobacterium* to produce SCFA in the human intestine ([@B45]).

Our study has limitations. Our results showed that dysbiosis of gut microflora composition during the course of CIA and the homeostasis was restored by acarbose treatment. These changes are associated with decreased Th17 cells and increased in Treg cells in the gut. However, our study did not provide direct evidence as to which bacterium directly contribute to the inflammation or anti-inflammatory effect, or contribute to maintain the balance between Th17 and Treg cells. Rather, our study shows an association between the reduced inflammation and restored gut microflora in acarbose treated mice. Further studies may need to focus on influence of acarbose on changes of commensal bacteria and their metabolites since commensal bacteria have been shown to selectively expand Treg cells ([@B52]).

In summary, changes in the gut microbiome and fermentation products in mice treated with acarbose have been associated with reduction of inflammation and with enhanced longevity ([@B53]) which may be due to decreased inflammation. The anti-arthritis effect of acarbose is best executed in prophylaxis of arthritis in the CIA model but less potent when treatment started at the time of arthritis induction. Considering the clinical usage of acarbose in management of RA, acarbose may have a place in preventing the development of RA in at-risk populations and in maintaining remission status of RA patients who have reached remission after treatment with DMARDs.
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